release notes Open Targets Platform 20.06 has been released! We have a new release of the Open Targets Platform with new disease terms including COVID-19, new chemical probes, updates to Open Targets Genetics evidence and more.
Open Targets Platform Open Targets Platform: adding FDA data with Scala and Spark Leveraging Spark and Scala to implement a performant ELT pipeline to integrate the FDA Adverse Event Reporting System into the Open Targets Platform
release notes Open Targets Platform 20.04 has been released! We have a new release of the Open Targets Platform with new target safety data, new target tractability modalities, more chemical probes and new associations.
Q&A Prioritising your list of potential drug targets with tractability assessments How tractable is a drug target? In this Open Targets Q&A, we explore the ChEMBL tractability (druggability) pipeline implemented in the Open Targets Platform.
Open Targets Genetics GWAS causal inference in Open Targets Finding GWAS causal inference for target identification and prioritisation using Open Targets Genetics and the Open Targets Platform.
Open Targets Platform Open Targets in the time of Covid-19 In this blog, I explore the utility and limitations of COVID-19 data in the Open Targets Platform to find treatments for this new infectious disease.
Q&A Special Q&A with Gosia Trynka, Open Targets Experimental Science director We're delighted to have caught up with Gosia Trynka, our new Experimental Science director, for a very special Q&A on Open Targets science and more.
Genetics releases Open Targets Genetics: new release is out We're pleased to announce the latest release of Open Targets Genetics (March 2020) is out with a new locus-to-gene score to prioritise protein-coding genes at all published GWAS-associated loci.
release notes Open Targets Platform: release 20.02 is out We have a new release of the Open Targets Platform with a brand new data source, Open Targets Genetics Portal, more chemical probes and new intOGen data.
Cancer An Open Targets Away Day with The Institute of Cancer Research Open Targets meets colleagues at the Institute of Cancer Research in London: potential collaboration ahead of us.
Q&A Getting to know intOGen, a resource for the identification of cancer driver genes Open Targets Q&A on identifying cancer driver genes and their mechanism of action with intOGen.
ontology EFO3: A community-driven ontology to advance clinical discoveries In the 19.11 release of the Open Targets Platform, we moved from EFO2 to EFO3. Here we explore what the new disease ontology means to Open Targets.
Open Targets Platform Using ChEMBL for target identification and prioritisation Open Targets Q&A on the identification of cancer driver genes and their mechanism of action using intOGen. Using ChEMBL for target identification and prioritisation
release notes Open Targets Platform: release 19.11 is out We have a new release of the Open Targets Platform: new EFO3, FDA pharmacovigilance data, new chemical probes, more targets, more evidence and associations.
A-Z From antibody to zinc finger: an A-Z of Open Targets As scientists discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. November is time for H.
release notes Open Targets Platform: release 19.09 is out We have a new release of the Open Targets Platform: more target-disease associations, more chemical probes and target enabling packages, and updated Elasticsearch.
Machine Learning Predicting Chemical Safety for Drug Discovery In this work, I illustrated the advantages of using multi‐label models for compounds toxicity assessment even when toxicity data is partially available.
Open Targets Platform On diseases and phenotypes, and how we learnt to stop worrying and ignore the distinction One of the questions that Open Targets Platform users ask is why we don't distinguish diseases from phenotypes. Ian Dunham tells us more in this blog post.
A-Z From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. This time we have a double bill: F and G.
release notes Open Targets Platform: release 19.06 is out We have a new release of the Open Targets Platform: more target safety information and new target-disease associations are some of the highlights in release 19.06.
Open Targets Genetics Open Targets Genetics new release is out We are pleased to announce the latest release of Open Targets Genetics is out with new colocalisation analysis, GWAS summary statistics and plenty more.
Q&A Using CRISPR priority score to identify targets in cancer drug discovery Open Targets Q&A on the first set of CRISPR screen results in cancer for target identification and prioritisation in drug discovery.
release notes Open Targets Platform: release 19.04 is out We have a new release of the Open Targets Platform: CRISPR-Cas9 data and target safety information are some of the highlights in release 19.04.
Open Targets Genetics Open Targets Genetics: new release is out We are excited to announce we have a new release of Open Targets Genetics, a variant-centric resource to find diseases associations for drug discovery.
Q&A Avoiding confusion in disease biology with ontologies Open Targets Q&A on the importance of describing diseases with ontologies when searching for new therapeutic targets in drug discovery.
